Amikacin sulfate
Based on 30 publication(s) in Google Scholar
Amikacin sulfate (BAY 41-6551 sulfate) is an aminoglycoside antibiotic and a semisynthetic analog of kanamycin. Amikacin sulfate is bactericidal, acting directly on the 30S and 50S bacerial ribosomal subunits to inhibit protein synthesis. Amikacin sulfate is very active against most Gram-negative bacteria including gentamicin- and tobramycin-resistant strains. Amikacin sulfate also inhibits the infections caused by susceptible Nocardia and nontuberculous mycobacteria.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 149022-22-0
- Formula: C22H43N5O13.9/5H2O4S
- Molecular Weight:762.14
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Glycoside Compound Library
HY-L042
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Animal Drug Library
HY-L218
Publications Citing Use of MedChemExpress (MCE) Amikacin sulfate
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- J Exp Clin Cancer Res. 2025 Nov 7;44(1):302. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- EBioMedicine. 2025 Jul:117:105776. [Abstract]
- J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]
- Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]
- Antibiotics (Basel). 2021 Sep 14;10(9):1110. [Abstract]
- Int J Antimicrob Agents. 2025 Oct;66(4):107551. [Abstract]
- Int J Antimicrob Agents. 2018 Aug;52(2):269-271. [Abstract]
- Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702. [Abstract]
- ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]
- Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0024925. [Abstract]
- Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0094524. [Abstract]
- J Antimicrob Chemother. 2026 Jun 3;81(7):dkag204. [Abstract]
- Microbiol Spectr. 2026 Mar 30;14(5):e0147325. [Abstract]
- Microbiol Spectr. 2025 Jul;13(7):e0307424. [Abstract]
- J Antimicrob Chemother. 2020 Sep 1;75(9):2609-2615. [Abstract]
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- Pathogens. 2025 Mar 21;14(4):302. [Abstract]
- ACS Chem Biol. 2022 Jan 21;17(1):39-53. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- Eur J Clin Microbiol Infect Dis. 2025 Sep 29. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1493-1500. [Abstract]
- Curr Microbiol. 2021 Dec 14;79(1):12. [Abstract]
- Int J Med Microbiol. 2023 Mar 28;313(2):151578. [Abstract]
- Authorea. 2025 Sep 17.
- bioRxiv. 2025 May 30.
- bioRxiv. 2024 May 10.
Customer Validation & Images
-
Microbiological Assay
All Antibiotic Isoforms
More
Biological Activity
|
Aminoglycoside |
Amikacin offers definite advantages for treating infections caused by organisms resistant to other aminoglycosides. Amikaci is affected by relatively few arninoglycoside-modifying enzymes. Amikacin is useful in the treatment of infections caused by Nocardia asteroides, Mycobacterium avium-intracellulare, and certain species of "rapid-growing" mycobacteria (that is, M. chelonae and M. fortuitumi)[1].
Amikacin (100-1500 μM) causes a reliable dose-dependent loss of lateral line zebrafish hair cells with a LD50 value of 453 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Fischer 344 rats (40-50-day-old)[3]
-
Dosage:320 mg/kg
-
Administration:Subcutaneous injection; daily; for 10 days
-
Result:Induced hearing loss in rats.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 149022-22-0
-
Appearance Solid
-
Molecular Weight 762.14
-
Formula C22H43N5O13.9/5H2O4S
-
Color White to off-white
-
SMILES
O[C@@H]1[C@H]([C@@H](C[C@H](N)[C@H]1O[C@@]([C@@H]([C@@H](O)[C@@H]2O)O)([H])O[C@@H]2CN)NC([C@@H](O)CCN)=O)O[C@@]([C@@H]([C@@H](N)[C@@H]3O)O)([H])O[C@@H]3CO.O=[S](O)(O)=O.[9/5]
-
Synonyms
BAY 41-6551 sulfate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (30)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
J Exp Clin Cancer Res
2025 Nov 7;44(1):302. PMID: 41204299 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
EBioMedicine
Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin. [Abstract]2025 Jul:117:105776. PMID: 40449326 -
J Clin Microbiol
Luciferase reporter mycobacteriophage (TM4:: GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. [Abstract]2025 Aug 20:e0084125. PMID: 40833127 -
Commun Biol
The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]2025 Oct 6;8(1):1425. PMID: 41053365 -
Antibiotics (Basel)
Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. [Abstract]2021 Sep 14;10(9):1110. PMID: 34572692 -
Int J Antimicrob Agents
Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]2025 Oct;66(4):107551. PMID: 40499596 -
Int J Antimicrob Agents
Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]2018 Aug;52(2):269-271. PMID: 29559273 -
Appl Microbiol Biotechnol
2022 Apr;106(7):2689-2702. PMID: 35338386 -
ACS Infect Dis
Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]2024 Apr 12;10(4):1327-1338. PMID: 38567846 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 Jul 2;69(7):e0024925. PMID: 40407337 -
Antimicrob Agents Chemother
2024 Dec 5;68(12):e0094524. PMID: 39470202 -
J Antimicrob Chemother
Harnessing metabolic dependence-driven antibiotic synergy to eradicate tolerant Pseudomonas aeruginosa. [Abstract]2026 Jun 3;81(7):dkag204. PMID: 42267541 -
Microbiol Spectr
Eravacycline for Mycobacterium abscessus infections: pharmacodynamic advantages of long-acting post-antibiotic effects and weekly dosing regimens. [Abstract]2026 Mar 30;14(5):e0147325. PMID: 41910138 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 Jul;13(7):e0307424. PMID: 40387379 -
J Antimicrob Chemother
Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. [Abstract]2020 Sep 1;75(9):2609-2615. PMID: 32591806 -
J Antimicrob Chemother
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]2020 Jul 1;75(7):1850-1858. PMID: 32154866 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732
Amikacin sulfate purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]
Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.
-
Pathogens
N-Acetylcysteine as a Host-Directed Therapy Against Clarithromycin-Resistant Mycobacterium abscessus. [Abstract]2025 Mar 21;14(4):302. PMID: 40333083 -
ACS Chem Biol
Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]2022 Jan 21;17(1):39-53. PMID: 34908399 -
-
Eur J Clin Microbiol Infect Dis
Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]2025 Sep 29. PMID: 41023358 -
Eur J Clin Microbiol Infect Dis
Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa. [Abstract]2025 Jun;44(6):1493-1500. PMID: 40056304 -
Curr Microbiol
Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa. [Abstract]2021 Dec 14;79(1):12. PMID: 34905092 -
Int J Med Microbiol
Antibacterial and antibiofilm efficacy of repurposing drug hexestrol against methicillin-resistant Staphylococcus aureus. [Abstract]2023 Mar 28;313(2):151578. PMID: 37001448 -
-
-
Solvent & Solubility
H2O : 25 mg/mL (32.80 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Edson, R.S. and C.L. Terrell, The aminoglycosides. Mayo Clin Proc, 1999. 74(5): p. 519-28. [Content Brief]
[2]. Ristuccia AM, et al. An overview of amikacin. Ther Drug Monit. 1985;7(1):12-25. [Content Brief]
[3]. Siân R Kitcher, et al. ORC-13661 Protects Sensory Hair Cells From Aminoglycoside and Cisplatin Ototoxicity. JCI Insight. 2019 Aug 8;4(15):e126764. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.3121 mL | 6.5605 mL | 13.1209 mL | 32.8024 mL |
| 5 mM | 0.2624 mL | 1.3121 mL | 2.6242 mL | 6.5605 mL | |
| 10 mM | 0.1312 mL | 0.6560 mL | 1.3121 mL | 3.2802 mL | |
| 15 mM | 0.0875 mL | 0.4374 mL | 0.8747 mL | 2.1868 mL | |
| 20 mM | 0.0656 mL | 0.3280 mL | 0.6560 mL | 1.6401 mL | |
| 25 mM | 0.0525 mL | 0.2624 mL | 0.5248 mL | 1.3121 mL | |
| 30 mM | 0.0437 mL | 0.2187 mL | 0.4374 mL | 1.0934 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Amikacin sulfate Related Classifications
HY-107813 Related Classifications
Powered by Bioz